Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation
09 Abril 2024 - 7:30AM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced the
successful completion of an animal study evaluating the Company’s
proprietary catheter-based sensing technology for use in the renal
artery.
The preclinical porcine model study was designed
to assess the ability of the Company’s catheter-based sensing
technology to effectively sense and target individual nerves
surrounding the renal artery. For the study, epivascular injections
of ethanol were given to target nerves and the Company’s sensing
technology was successfully able to capture the down-regulated
nerve signal of the treated nerve from within the renal artery, as
well as the return to normal signal post ethanol treatment. These
results strongly demonstrate the potential of Autonomix’s sensing
technology to successfully locate nerves around the renal artery.
These nerves include those responsible for regulating blood
pressure and are the target of recently approved renal denervation
procedures for hypertension.
Lori Bisson, Chief Executive Officer of
Autonomix, commented, “Currently approved procedures using renal
denervation for the treatment of hypertension involve ablating the
general area where nerves are believed to exist without visibility
of the actual nerves and without the ability to differentiate
between those nerves causing hypertension and those serving other
important functions. Essentially, they are treating blindly,
without assurance of hitting the right target. The successful
completion of this preclinical study provides us with confidence in
the potential of our sensing technology to ultimately make renal
denervation safer, faster, and more effective. While we are
primarily focused on successful completion of our first in man
study for pancreatic cancer pain, we are investigating exciting
uses for the technology in other indications. We believe that based
on our growing body of data, our technology may be able to address
the significant unmet need for a tool that can successfully sense,
target and influence neuronal signals safely and reliably across
multiple indications, from pain to hypertension. We are committed
to progressing the development of our technology forward with the
goal of bringing benefit to patients in need.”
The Company’s catheter-based sensing technology
is being developed to do two things: sense neural signals
associated with pain or disease and precisely target those nerves
for treatment. Autonomix believes this technology is a better
alternative to the current approaches commonly used today, where
doctors either rely on systemic drugs like opioids that lose
effectiveness and have unwanted side effects or treat suspected
areas blindly in hopes of hitting the right nerves, an approach
that is often inaccurate and can miss the target and even cause
collateral damage to surrounding parts of the body.
The Company is initially developing its
technology to address pancreatic cancer-related pain. Current
approaches, primarily relying on opioids or invasive ethanol
injections, can provide only limited relief and may lead to risky
side effects. For more information about the Company’s technology,
please visit autonomix.com.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain, a condition that can cause debilitating
pain and needs an effective solution. However, our technology
constitutes a platform with the potential to address dozens of
indications, including in cardiology, renal denervation and chronic
pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward looking statements in this press release
include, without limitation, the potential of the technology to
treat hypertension and to complete its clinical study in pancreatic
cancer pain. Such forward-looking statements can be identified by
the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’
‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’
‘plans,’ and ‘proposes.’
Although Autonomix Medical, Inc. (or Autonomix)
believes that the expectations reflected in these forward-looking
statements are based on reasonable assumptions, there are a number
of risks and uncertainties that could cause actual results to
differ materially from such forward-looking statements. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading “Risk Factors” and elsewhere in the offering circular filed
with the U.S. Securities and Exchange Commission (“SEC”) on January
26, 2024. Forward-looking statements speak only as of the date of
the document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media ContactJTC Team, LLCJenene
Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Autonomix Medical (NASDAQ:AMIX)
Gráfica de Acción Histórica
De May 2023 a May 2024